Overview

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole in adult participants with schizophrenia or bipolar I disorder. To establish the similarity of aripiprazole concentrations following the final administration of aripiprazole into the gluteal muscle site, and to establish the similarity of aripiprazole exposure following the final administration of aripiprazole into the gluteal muscle site.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborator:
PRA Health Sciences
Treatments:
Aripiprazole